Compare Gilead Sciences, Inc. (GILD) vs Upwork Inc (UPWK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Upwork Inc — how do they compare? Gilead Sciences, Inc. trades at $135.55 (market cap $168.35B), while Upwork Inc trades at $8.34 (market cap $1.04B). The key difference: Gilead Sciences, Inc. is far larger — about 161.9× Upwork Inc's market cap, and Gilead Sciences, Inc. pays a 2.42% dividend while Upwork Inc pays none. Which is the better fit depends on your goals.
| GILD | UPWK | |
|---|---|---|
Market Cap | $168.35B | $1.04B |
Sector | Health | Industrials |
52-Week High | $155.80 | $22.11 |
52-Week Low | $110.56 | $7.84 |
Enterprise Value | $191.42B | $806.15M |
Dividend Yield | 2.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $136.73, up 2.76% on the day, with a bullish technical signal and strong analyst consensus. Recent Q2 2026 earnings beat revenue estimates despite a net loss driven by acquisition costs, while HIV drug sales and raised guidance provide fundamental support. The stock is near its pivot point of $136, with resistance at $137 and support at $134.
Outlook remains positive given robust HIV franchise growth and pipeline advancements, but risks include patent cliffs, high debt, and profitability volatility. With 67% of analysts rating it a Buy and a consensus price target of $151.22, the stock offers potential upside, though investors must weigh execution risks against growth catalysts.
UPWK is trading at $8.25, down 16.12% amid weak guidance overshadowing a recent Q2 earnings beat. The stock shows bearish technical signals with key support at $8.00. Fundamentally, revenue grew to $787.78M in 2025 with a net income margin of 12.93%, though earnings have been mixed with three misses in the last four quarters. Recent news highlights concerns over declining active clients and AI-driven market shifts.
The outlook is cautious; while valuation ratios like P/E of 10.71 appear reasonable, near-term risks from competitive pressures and investor lawsuits pose headwinds. Analyst consensus is a Buy with a $9.25 target, suggesting potential upside if execution improves, but sentiment remains fragile post-earnings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Upwork Inc
Upwork Inc is a United States-based company that operates an online marketplace that enables businesses to find and work with highly-skilled independent professionals. The develops platform for hiring and freelancing purposes. Its products offering include Upwork Basic, Upwork Plus, Upwork Business, Upwork Enterprise, and Upwork Payroll. The business generates revenue from Talent and Clients across the USA, India, the Philippines and the rest of the world. Substantial income is derived from providing services to Clients.
Read more on UPWK →
